Compare Organon & Co. Common Stock (OGN) vs Raytheon Technologies Corp (RTX) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

RTX trades at $186.66, up 0.37% on the day, with a bearish technical signal but strong fundamental momentum. The company reported revenue of $88.60 billion in 2025, with net income of $6.73 billion and a profit margin of 7.59%. Recent earnings beats and a $289 billion backlog highlight robust demand in aerospace and defense. Analyst consensus is bullish with a $233.55 price target, though technical indicators show near-term resistance.

The outlook for RTX is positive, driven by sustained defense spending and commercial aviation recovery. Investment opportunities include earnings growth and dividend yield, while risks involve execution on the large backlog and potential defense budget fluctuations. The stock offers value if it can maintain its growth trajectory amid geopolitical tailwinds.